Back to top
February 9, 2018
CURE-backed research finds biomarker to halt seizures post brain injury
Research, CURE News

As reported by Katie Pfaff, BioWorld MedTech:

Research may have pinpointed a biomarker for epilepsy after stroke, a condition with unpredictable onset and few treatment options. Funded by nonprofit Citizens United for Research in Epilepsy (CURE), the Italian-based research team has discovered a protein in animal model tied to development of seizures following brain injury.

Lead by Annamaria Vezzani, researchers at Milan's Mario Negri Institute for Pharmacological Research have identified the biomarker HMGB1, which was found to spike among studied animals before development of epilepsy. Research was conducted in a rat model and may point to possible inception of epilepsy after injury to the brain. HMGB1 is commonly associated with neuroinflammation in the brain after injury and may mean such inflammation can be treated with medication to hold off seizures or decrease their severity.

"With this research, Vezzani and her team have provided hope that a treatment for preventing acquired epilepsy before it occurs is on the horizon," said Kate Carr, CEO, CURE.

Learn More

 

Related News

February 21, 2018
GW Pharmaceuticals Announces That Pipeline Compound...

GW Pharmaceuticals announced that a Phase 2a proof-of-concept study of a pipeline compound GWP42006 in adult patients with focal seizures did...

February 20, 2018
News from Abroad: Xenon Pharmaceuticals Advances Second...

Xenon Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901.

February 19, 2018
Maternal use of epilepsy drug may decrease school...

Pregnant women who used valproate had children with significantly lower school performance vs. children who were exposed to lamotrigine or not...